Business
AACR 2019
AACR 2019.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 0679V Angle PLC 04 April 2019 \n\n\n\n\nFor immediate release\n\n\n 4 April 2019\n\n\n\n \nANGLE plc (\"the Company\")\n \nANGLE'S PARSORTIX SYSTEM SHOWCASED IN SIX POSTER PRESENTATIONS AT LEADING CANCER CONFERENCE AACR 2019 \n \nCustomers publish data from four independent studies demonstrating success with ANGLE's Parsortix liquid biopsy system \n \nANGLE publishes detailed analytical performance data of Parsortix and HyCEAD Ziplex downstream analysis systems \n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, today announces that its ParsortixTM system has been showcased by a number of customers in poster presentations at the American Association for Cancer Research conference (AACR) 2019, in Atlanta, Georgia, United States from 29 March to 3 April 2019. \n \nIn addition, ANGLE presented detailed performance data from the optimisation of its ovarian cancer assay for both its Parsortix and HyCEAD Ziplex systems at the conference.\n \nWork by the University of Athens lead by Professor Evi Lianidou was particularly important as it demonstrated the superior performance of the Parsortix system in head and neck squamous cell carcinoma (HNSCC) in matched samples when compared with an antibody-based CTC enrichment approach. Superior sensitivity of Parsortix was demonstrated for the expression of multiple genes. \n \nExpression of PD-L1 is of particular importance as it is the target for leading immunotherapy drugs including Nivolumab (Opdivo®) manufactured by Bristol Myers Squibb and Pembrolizumab (Keytruda®) manufactured by Merck. These drugs can be very effective for some patients. Only a minority of patients will respond and it is crucial to be able to accurately identify which ones. In the matched comparison of PD-L1 expression in 50 HNSCC patients, the Parsortix system identified 9/50 with PD-L1 expression whereas the antibody-based approach only identified 4/50. Around 1 in 5 patients may be expected to respond to PD-L1 immunotherapies so the Parsortix result is consistent with expected detection levels. \n \nAs well as this work by the University of Athens, ANGLE's Parsortix system has been showcased in the following poster presentations at AACR 2019:\n \nPoster Present...